[1]
Limanaqi F, Gambardella S, Biagioni F, Busceti CL, Fornai F. Epigenetic Effects Induced by Methamphetamine and Methamphetamine-Dependent Oxidative Stress. Oxidative medicine and cellular longevity. 2018:2018():4982453. doi: 10.1155/2018/4982453. Epub 2018 Jul 22
[PubMed PMID: 30140365]
Level 2 (mid-level) evidence
[2]
Kronstrand R, Guerrieri D, Vikingsson S, Wohlfarth A, Gréen H. Fatal Poisonings Associated with New Psychoactive Substances. Handbook of experimental pharmacology. 2018:252():495-541. doi: 10.1007/164_2018_110. Epub
[PubMed PMID: 30105471]
[3]
Simmler LD, Liechti ME. Pharmacology of MDMA- and Amphetamine-Like New Psychoactive Substances. Handbook of experimental pharmacology. 2018:252():143-164. doi: 10.1007/164_2018_113. Epub
[PubMed PMID: 29633178]
[4]
Courtney KE, Ray LA. Methamphetamine: an update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug and alcohol dependence. 2014 Oct 1:143():11-21. doi: 10.1016/j.drugalcdep.2014.08.003. Epub 2014 Aug 17
[PubMed PMID: 25176528]
[5]
Mellos E, Paparrigopoulos T. Substance use during the COVID-19 pandemic: What is really happening? Psychiatrike = Psychiatriki. 2022 Mar 28:33(1):17-20. doi: 10.22365/jpsych.2022.072. Epub 2022 Feb 21
[PubMed PMID: 35255473]
[6]
Cisneros IE, Ghorpade A. Methamphetamine and HIV-1-induced neurotoxicity: role of trace amine associated receptor 1 cAMP signaling in astrocytes. Neuropharmacology. 2014 Oct:85():499-507. doi: 10.1016/j.neuropharm.2014.06.011. Epub 2014 Jun 17
[PubMed PMID: 24950453]
[7]
Kevil CG, Goeders NE, Woolard MD, Bhuiyan MS, Dominic P, Kolluru GK, Arnold CL, Traylor JG, Orr AW. Methamphetamine Use and Cardiovascular Disease. Arteriosclerosis, thrombosis, and vascular biology. 2019 Sep:39(9):1739-1746. doi: 10.1161/ATVBAHA.119.312461. Epub 2019 Aug 21
[PubMed PMID: 31433698]
[8]
Tobolski J, Sawyer DB, Song SJ, Afari ME. Cardiovascular disease associated with methamphetamine use: a review. Heart failure reviews. 2022 Nov:27(6):2059-2065. doi: 10.1007/s10741-022-10261-7. Epub 2022 Jul 18
[PubMed PMID: 35844009]
[9]
Indave BI, Sordo L, Bravo MJ, Sarasa-Renedo A, Fernández-Balbuena S, De la Fuente L, Sonego M, Barrio G. Risk of stroke in prescription and other amphetamine-type stimulants use: A systematic review. Drug and alcohol review. 2018 Jan:37(1):56-69. doi: 10.1111/dar.12559. Epub 2017 May 8
[PubMed PMID: 28485090]
Level 1 (high-level) evidence
[10]
Citron BP, Halpern M, McCarron M, Lundberg GD, McCormick R, Pincus IJ, Tatter D, Haverback BJ. Necrotizing angiitis associated with drug abuse. The New England journal of medicine. 1970 Nov 5:283(19):1003-11
[PubMed PMID: 4394271]
[11]
Syed RH, Moore TL. Methylphenidate and dextroamphetamine-induced peripheral vasculopathy. Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases. 2008 Feb:14(1):30-3. doi: 10.1097/RHU.0b013e3181639aaa. Epub
[PubMed PMID: 18431096]
[12]
Loewenhardt B, Bernhard M, Pierskalla A, Neumann-Haefelin T, Hofmann E. Neurointerventional treatment of amphetamine-induced acute occlusion of the middle cerebral artery by intracranial balloon angioplasty. Clinical neuroradiology. 2013 Jun:23(2):137-43. doi: 10.1007/s00062-011-0122-1. Epub 2011 Dec 16
[PubMed PMID: 22173373]
[13]
Leithäuser B, Langheinrich AC, Rau WS, Tillmanns H, Matthias FR. A 22-year-old woman with lower limb arteriopathy. Buerger's disease, or methamphetamine- or cannabis-induced arteritis? Heart and vessels. 2005 Feb:20(1):39-43
[PubMed PMID: 15700202]
[15]
Angrist B, Corwin J, Bartlik B, Cooper T. Early pharmacokinetics and clinical effects of oral D-amphetamine in normal subjects. Biological psychiatry. 1987 Nov:22(11):1357-68
[PubMed PMID: 3663788]
[16]
Heal DJ, Smith SL, Gosden J, Nutt DJ. Amphetamine, past and present--a pharmacological and clinical perspective. Journal of psychopharmacology (Oxford, England). 2013 Jun:27(6):479-96. doi: 10.1177/0269881113482532. Epub 2013 Mar 28
[PubMed PMID: 23539642]
Level 3 (low-level) evidence
[17]
Santagati NA, Ferrara G, Marrazzo A, Ronsisvalle G. Simultaneous determination of amphetamine and one of its metabolites by HPLC with electrochemical detection. Journal of pharmaceutical and biomedical analysis. 2002 Sep 5:30(2):247-55
[PubMed PMID: 12191709]
[18]
Brams M, Mao AR, Doyle RL. Onset of efficacy of long-acting psychostimulants in pediatric attention-deficit/hyperactivity disorder. Postgraduate medicine. 2008 Sep:120(3):69-88. doi: 10.3810/pgm.2008.09.1909. Epub
[PubMed PMID: 18824827]
[19]
Cody JT, Schwarzhoff R. Fluorescence polarization immunoassay detection of amphetamine, methamphetamine, and illicit amphetamine analogues. Journal of analytical toxicology. 1993 Jan-Feb:17(1):23-33
[PubMed PMID: 8429622]
[20]
Spiller HA, Ryan ML, Weston RG, Jansen J. Clinical experience with and analytical confirmation of "bath salts" and "legal highs" (synthetic cathinones) in the United States. Clinical toxicology (Philadelphia, Pa.). 2011 Jul:49(6):499-505. doi: 10.3109/15563650.2011.590812. Epub
[PubMed PMID: 21824061]
[21]
DePriest AZ, Knight JL, Doering PL, Black DL. Pseudoephedrine and false-positive immunoassay urine drug tests for amphetamine. Pharmacotherapy. 2013 May:33(5):e88-9. doi: 10.1002/phar.1216. Epub 2012 Oct 12
[PubMed PMID: 23065913]
[22]
Bedussi F, Acerbis E, Noseda R, Demagistri D, Zamprogno E, Ceschi A. False-positive urine screen test for MDMA in a patient exposed to mebeverine. British journal of clinical pharmacology. 2021 May:87(5):2397-2398. doi: 10.1111/bcp.14624. Epub 2020 Nov 16
[PubMed PMID: 33200465]
[23]
Leclercq M, Soichot M, Delhotal-Landes B, Bourgogne E, Gourlain H, Mégarbane B, Labat L. False positive amphetamines and 3,4-methylenedioxymethamphetamine immunoassays in the presence of metoprolol-two cases reported in clinical toxicology. Journal of analytical toxicology. 2020 Mar 7:44(2):200-205. doi: 10.1093/jat/bkz051. Epub
[PubMed PMID: 31384953]
Level 3 (low-level) evidence
[24]
Wijngaard R, Parra-Robert M, Marés L, Escalante A, Salgado E, González-de-la-Presa B, To-Figueras J, Brunet M. Tetracaine from urethral ointment causes false positive amphetamine results by immunoassay. Clinical toxicology (Philadelphia, Pa.). 2021 Jun:59(6):500-505. doi: 10.1080/15563650.2020.1834114. Epub 2020 Oct 28
[PubMed PMID: 33112680]
[25]
Vorce SP, Holler JM, Cawrse BM, Magluilo J Jr. Dimethylamylamine: a drug causing positive immunoassay results for amphetamines. Journal of analytical toxicology. 2011 Apr:35(3):183-7
[PubMed PMID: 21439156]
[26]
Kaplan J, Shah P, Faley B, Siegel ME. Case Reports of Aripiprazole Causing False-Positive Urine Amphetamine Drug Screens in Children. Pediatrics. 2015 Dec:136(6):e1625-8. doi: 10.1542/peds.2014-3333. Epub 2015 Nov 2
[PubMed PMID: 26527556]
Level 3 (low-level) evidence
[27]
Liu L, Wheeler SE, Rymer JA, Lower D, Zona J, Peck Palmer OM, Tamama K. Ranitidine interference with standard amphetamine immunoassay. Clinica chimica acta; international journal of clinical chemistry. 2015 Jan 1:438():307-8. doi: 10.1016/j.cca.2014.09.012. Epub 2014 Sep 19
[PubMed PMID: 25242739]
[28]
Pisani F, Oteri G, Costa C, Di Raimondo G, Di Perri R. Effects of psychotropic drugs on seizure threshold. Drug safety. 2002:25(2):91-110
[PubMed PMID: 11888352]
[29]
Kreuzer P, Landgrebe M, Wittmann M, Schecklmann M, Poeppl TB, Hajak G, Langguth B. Hypothermia associated with antipsychotic drug use: a clinical case series and review of current literature. Journal of clinical pharmacology. 2012 Jul:52(7):1090-7. doi: 10.1177/0091270011409233. Epub 2011 Sep 28
[PubMed PMID: 21956608]
Level 2 (mid-level) evidence
[30]
Shiloh R, Schapir L, Bar-Ziv D, Stryjer R, Konas S, Louis R, Hermesh H, Munitz H, Weizman A, Valevski A. Association between corneal temperature and mental status of treatment-resistant schizophrenia inpatients. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. 2009 Sep:19(9):654-8. doi: 10.1016/j.euroneuro.2009.04.010. Epub 2009 Jun 2
[PubMed PMID: 19493658]
[31]
Evers SS, Calcagnoli F, van Dijk G, Scheurink AJ. Olanzapine causes hypothermia, inactivity, a deranged feeding pattern and weight gain in female Wistar rats. Pharmacology, biochemistry, and behavior. 2010 Nov:97(1):163-9. doi: 10.1016/j.pbb.2010.05.029. Epub 2010 Jun 4
[PubMed PMID: 20570692]
[32]
Ray LA, Bujarski S, Courtney KE, Moallem NR, Lunny K, Roche D, Leventhal AM, Shoptaw S, Heinzerling K, London ED, Miotto K. The Effects of Naltrexone on Subjective Response to Methamphetamine in a Clinical Sample: a Double-Blind, Placebo-Controlled Laboratory Study. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2015 Sep:40(10):2347-56. doi: 10.1038/npp.2015.83. Epub 2015 Mar 24
[PubMed PMID: 25801501]
Level 1 (high-level) evidence
[33]
Moerke MJ, Banks ML, Cheng K, Rice KC, Negus SS. Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys. Drug and alcohol dependence. 2017 Dec 1:181():85-93. doi: 10.1016/j.drugalcdep.2017.09.020. Epub 2017 Oct 13
[PubMed PMID: 29040826]
[34]
Sakloth F, Negus SS. Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats. Experimental and clinical psychopharmacology. 2018 Apr:26(2):195-204. doi: 10.1037/pha0000183. Epub 2018 Mar 12
[PubMed PMID: 29528663]
[35]
Guterstam J, Jayaram-Lindström N, Berrebi J, Petrovic P, Ingvar M, Fransson P, Franck J. Cue reactivity and opioid blockade in amphetamine dependence: A randomized, controlled fMRI study. Drug and alcohol dependence. 2018 Oct 1:191():91-97. doi: 10.1016/j.drugalcdep.2018.06.023. Epub 2018 Jul 26
[PubMed PMID: 30096639]
Level 1 (high-level) evidence
[36]
Stoops WW, Pike E, Hays LR, Glaser PE, Rush CR. Naltrexone and bupropion, alone or combined, do not alter the reinforcing effects of intranasal methamphetamine. Pharmacology, biochemistry, and behavior. 2015 Feb:129():45-50. doi: 10.1016/j.pbb.2014.11.018. Epub 2014 Nov 29
[PubMed PMID: 25459104]
[37]
Winsløw F, Hansen NS, Jensen MB. Vertebral Artery Dissection Related to Amphetamine Abuse - A Case Report. Journal of central nervous system disease. 2020:12():1179573520939340. doi: 10.1177/1179573520939340. Epub 2020 Jun 30
[PubMed PMID: 32655281]
Level 3 (low-level) evidence
[38]
Wang AM, Suojanen JN, Colucci VM, Rumbaugh CL, Hollenberg NK. Cocaine- and methamphetamine-induced acute cerebral vasospasm: an angiographic study in rabbits. AJNR. American journal of neuroradiology. 1990 Nov-Dec:11(6):1141-6
[PubMed PMID: 2124040]
[39]
Buxton N, McConachie NS. Amphetamine abuse and intracranial haemorrhage. Journal of the Royal Society of Medicine. 2000 Sep:93(9):472-7
[PubMed PMID: 11089483]
[40]
Goyal P, Sethi P, Sharma S. Prevalence of recreational substance use in patients presenting with seizures to a tertiary care hospital. Epilepsy & behavior : E&B. 2021 Dec:125():108419. doi: 10.1016/j.yebeh.2021.108419. Epub 2021 Nov 24
[PubMed PMID: 34837845]
[41]
Madea B, Ruppel E, Prangenberg J, Krämer M, Doberentz E. Expression of heat shock proteins 27, 60, and 70 in amphetamine and cocaine associated deaths. Forensic science international. 2021 Dec:329():111088. doi: 10.1016/j.forsciint.2021.111088. Epub 2021 Oct 30
[PubMed PMID: 34773820]
[42]
Green AR, Cross AJ, Goodwin GM. Review of the pharmacology and clinical pharmacology of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). Psychopharmacology. 1995 Jun:119(3):247-60
[PubMed PMID: 7675958]
[43]
O'Connor AD, Rusyniak DE, Bruno A. Cerebrovascular and cardiovascular complications of alcohol and sympathomimetic drug abuse. The Medical clinics of North America. 2005 Nov:89(6):1343-58
[PubMed PMID: 16227066]
[44]
Pozoga J, Snopek G, Dabrowski M. [Acute coronary syndrome after amphetamine use in a young male with myocardial bridging--a case report]. Kardiologia polska. 2005 Apr:62(4):381-2
[PubMed PMID: 15928743]
Level 3 (low-level) evidence
[45]
Kueh SA, Gabriel RS, Lund M, Sutton T, Bradley J, Kerr AJ, Looi JL. Clinical Characteristics and Outcomes of Patients with Amphetamine-Associated Cardiomyopathy in South Auckland, New Zealand. Heart, lung & circulation. 2016 Nov:25(11):1087-1093. doi: 10.1016/j.hlc.2016.03.008. Epub 2016 Apr 20
[PubMed PMID: 27185546]
[46]
Jacobs W. Fatal amphetamine-associated cardiotoxicity and its medicolegal implications. The American journal of forensic medicine and pathology. 2006 Jun:27(2):156-60
[PubMed PMID: 16738435]
[47]
Ayme-Dietrich E, Lawson R, Côté F, de Tapia C, Da Silva S, Ebel C, Hechler B, Gachet C, Guyonnet J, Rouillard H, Stoltz J, Quentin E, Banas S, Daubeuf F, Frossard N, Gasser B, Mazzucotelli JP, Hermine O, Maroteaux L, Monassier L. The role of 5-HT(2B) receptors in mitral valvulopathy: bone marrow mobilization of endothelial progenitors. British journal of pharmacology. 2017 Nov:174(22):4123-4139. doi: 10.1111/bph.13981. Epub 2017 Oct 15
[PubMed PMID: 28806488]
[48]
Naqvi TZ, Gross SB. Anorexigen-induced cardiac valvulopathy and female gender. Current women's health reports. 2003 Apr:3(2):116-25
[PubMed PMID: 12628081]
[49]
Westover AN, Nakonezny PA. Aortic dissection in young adults who abuse amphetamines. American heart journal. 2010 Aug:160(2):315-21. doi: 10.1016/j.ahj.2010.05.021. Epub
[PubMed PMID: 20691838]
[50]
Swalwell CI, Davis GG. Methamphetamine as a risk factor for acute aortic dissection. Journal of forensic sciences. 1999 Jan:44(1):23-6
[PubMed PMID: 9987866]
[51]
Hu HY, Wei SY, Pan CH. Rhabdomyolysis observed at forensic autopsy: a series of 52 cases. Forensic science, medicine, and pathology. 2018 Dec:14(4):424-431. doi: 10.1007/s12024-018-0003-x. Epub 2018 Jul 28
[PubMed PMID: 30056625]
Level 3 (low-level) evidence
[52]
Farah R, Farah R. Ecstasy (3,4-methylenedioxymethamphetamine)-induced inappropriate antidiuretic hormone secretion. Pediatric emergency care. 2008 Sep:24(9):615-7. doi: 10.1097/PEC.0b013e3181850c91. Epub
[PubMed PMID: 18797371]
[53]
Panikkath R, Panikkath D. Amphetamine-related ischemic colitis causing gastrointestinal bleeding. Proceedings (Baylor University. Medical Center). 2016 Jul:29(3):325-6
[PubMed PMID: 27365888]
[54]
Green PA, Battersby C, Heath RM, McCrossan L. A fatal case of amphetamine induced ischaemic colitis. Annals of the Royal College of Surgeons of England. 2017 Sep:99(7):e200-e201. doi: 10.1308/rcsann.2016.0350. Epub
[PubMed PMID: 28853604]
Level 3 (low-level) evidence
[55]
Kurtz B, Alshoubi A, Nguyen K, Gehres E. Methamphetamine-Induced Bowel Ischemia in a 50-Year-Old Male. Case reports in critical care. 2022:2022():9690034. doi: 10.1155/2022/9690034. Epub 2022 Apr 5
[PubMed PMID: 35402052]
Level 3 (low-level) evidence
[56]
Attaran H. Fatal Small Intestinal Ischemia Due to Methamphetamine Intoxication: Report of a Case With Autopsy Results. Acta medica Iranica. 2017 May:55(5):344-347
[PubMed PMID: 28724276]
Level 3 (low-level) evidence
[57]
Medhus S, Rognli EB, Gossop M, Holm B, Mørland J, Bramness JG. Amphetamine-induced psychosis: Transition to schizophrenia and mortality in a small prospective sample. The American journal on addictions. 2015 Oct:24(7):586-9. doi: 10.1111/ajad.12274. Epub 2015 Sep 1
[PubMed PMID: 26332037]
[58]
Ginovart N, Farde L, Halldin C, Swahn CG. Changes in striatal D2-receptor density following chronic treatment with amphetamine as assessed with PET in nonhuman primates. Synapse (New York, N.Y.). 1999 Feb:31(2):154-62
[PubMed PMID: 10024013]
[59]
Boileau I, Dagher A, Leyton M, Gunn RN, Baker GB, Diksic M, Benkelfat C. Modeling sensitization to stimulants in humans: an [11C]raclopride/positron emission tomography study in healthy men. Archives of general psychiatry. 2006 Dec:63(12):1386-95
[PubMed PMID: 17146013]
[60]
Chen PI, Cao A, Miyagawa K, Tojais NF, Hennigs JK, Li CG, Sweeney NM, Inglis AS, Wang L, Li D, Ye M, Feldman BJ, Rabinovitch M. Amphetamines promote mitochondrial dysfunction and DNA damage in pulmonary hypertension. JCI insight. 2017 Jan 26:2(2):e90427. doi: 10.1172/jci.insight.90427. Epub 2017 Jan 26
[PubMed PMID: 28138562]
[61]
van Wolferen SA, Vonk Noordegraaf A, Boonstra A, Postmus PE. [Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping]. Nederlands tijdschrift voor geneeskunde. 2005 Jun 4:149(23):1283-8
[PubMed PMID: 15960135]
[62]
Zamanian RT, Hedlin H, Greuenwald P, Wilson DM, Segal JI, Jorden M, Kudelko K, Liu J, Hsi A, Rupp A, Sweatt AJ, Tuder R, Berry GJ, Rabinovitch M, Doyle RL, de Jesus Perez V, Kawut SM. Features and Outcomes of Methamphetamine-associated Pulmonary Arterial Hypertension. American journal of respiratory and critical care medicine. 2018 Mar 15:197(6):788-800. doi: 10.1164/rccm.201705-0943OC. Epub
[PubMed PMID: 28934596]
[63]
Seiden LS, Sabol KE, Ricaurte GA. Amphetamine: effects on catecholamine systems and behavior. Annual review of pharmacology and toxicology. 1993:33():639-77
[PubMed PMID: 8494354]
[64]
Ross LJ, Wilson M, Banks M, Rezannah F, Daglish M. Prevalence of malnutrition and nutritional risk factors in patients undergoing alcohol and drug treatment. Nutrition (Burbank, Los Angeles County, Calif.). 2012 Jul:28(7-8):738-43. doi: 10.1016/j.nut.2011.11.003. Epub 2012 Feb 21
[PubMed PMID: 22356728]
[65]
Laslett AM, Dietze P, Dwyer R. The oral health of street-recruited injecting drug users: prevalence and correlates of problems. Addiction (Abingdon, England). 2008 Nov:103(11):1821-5. doi: 10.1111/j.1360-0443.2008.02339.x. Epub
[PubMed PMID: 19032532]
[66]
Smart RJ, Rosenberg M. Methamphetamine abuse: medical and dental considerations. Journal of the Massachusetts Dental Society. 2005 Summer:54(2):44-6, 48-9
[PubMed PMID: 16149403]
[67]
Yeh TC, Lin YC, Chen LF, Chiang CP, Mao WC, Chang HA, Kao YC, Tzeng NS. Aripiprazole treatment in a case of amphetamine-induced delusional infestation. The Australian and New Zealand journal of psychiatry. 2014 Jul:48(7):681-2. doi: 10.1177/0004867414525849. Epub 2014 Feb 21
[PubMed PMID: 24563196]
Level 3 (low-level) evidence
[68]
Rhee KJ, Albertson TE, Douglas JC. Choreoathetoid disorder associated with amphetamine-like drugs. The American journal of emergency medicine. 1988 Mar:6(2):131-3
[PubMed PMID: 3355623]
[69]
Lundh H, Tunving K. An extrapyramidal choreiform syndrome caused by amphetamine addiction. Journal of neurology, neurosurgery, and psychiatry. 1981 Aug:44(8):728-30
[PubMed PMID: 7299411]